Introduction
Methods
Patients, Tumor tissues and cell lines
Group A | Group B | |||||
---|---|---|---|---|---|---|
Clinical features | Case | Mean age (years) | Age range (years) | Case | Mean age (years) | Age range (years) |
Histological Type | ||||||
Ductal | 45 | 34 | 25–40 | 59 | 53 | 41–77 |
Lobular | 2 | 28 | 20–35 | 0 | _ | _ |
Clinical Stage | ||||||
TNM Stage I | 1 | 40 | 40 | 2 | 48 | 45–50 |
TNM Stage II | 7 | 33 | 23–40 | 21 | 51 | 42–61 |
TNM Stage III | 36 | 35 | 20–40 | 33 | 53 | 41–77 |
TNM Stage IV | 3 | 37 | 36–38 | 3 | 57 | 48–72 |
Tumor Differentiation | ||||||
Grade 1 | 4 | 32 | 20–40 | 8 | 52 | 43–61 |
Grade 2 | 32 | 33 | 18–40 | 39 | 47 | 41–42 |
Grade 3 | 11 | 38 | 33–40 | 12 | 56 | 42–77 |
Lymph Node | ||||||
Positive | 33 | 35 | 26–40 | 48 | 52 | 42–77 |
Negative | 14 | 31 | 18–40 | 11 | 51 | 41–65 |
Microdissection and DNA Extraction
Deletion analysis of the candidate TSGs
Primers | Location | Analytical purpose | Forward Primer | Reverse Primer | Size (bp) |
---|---|---|---|---|---|
PHF2 Ex-18 | 9q22.32 | HD/HED | 5'-ACTCCTGCCTGCAGACCAC-3' | 5'-CCTGCTCTTCCTCGTAGTCG-3' | 168 |
FANCC Ex-2 | 9q22.32 | HD/HED | 5'-TGGCTCAAGATTCAGTAGATCTTTC-3' | 5'-TTTCAAGGCTTCATACATCTTCC-3' | 158 |
PHF2 promoter | -893 to -670 region | Methylation | 5'-GTGGTGTCCCAACCAGAAAC-3' | 5'-GGGACCCCGAGGATAAGATA-3' | 223 |
FANCC promoter | -319 to -144 region | Methylation | 5'-TTTTACCCCGTTGACAAAGC-3' | 5'-CGGTACTGCTCCAGTGTTCC-3' | 175 |
PTCH1 promoter | -715 to -420 region | Methylation | 5'-CGAGGAGCACAAGAAAGCAG-3' | 5'-AGAAAGAGCCAGCGAATCC-3' | 295 |
XPA promoter Ex.1 | -126 to +56 region | Methylation | 5'-AGGCGCTCTCACTCAGAAAG-3' | 5'-TCCGCGGGTTGCTCTAAA-3' | 182 |
PTCH1 Ex.*23 | Intron 22–23 to Ex.23 | SSCP | 5'-TCTAACCCACCCTCACCCTC-3' | 5'-ATTGCTAGGGCCAGAATGCC-3' | 226 |
PTCH1 Ex.23 | Ex.23 to Intron 23–24 | SSCP | 5'-TTCTGCCTCCGTGACTGTC-3' | 5'-CTCTAGGTCCCTTGGCTGC-3' | 265 |
PHF2 Ex. 18–19 | Coding regions of exons | Q-PCR | 5'-ACTCCTGCCTGCAGACCAC-3' | 5'-TCGACCGGGACTTAAAGATG-3' | 257 |
FANCC Ex. 7–8 | Coding regions of exons | Q-PCR | 5'-TGGAGGCTCTCCTCATCTGT-3' | 5'-GCATTCGATCCTTCTCAGACA-3' | 223 |
PTCH1 Ex. 1–2 | Coding regions of exons | Q-PCR | 5'-GACCGGGACTATCTGCA-3' | 5'-GAGGAGGCCCACAACC-3' | 186 |
β2 Microglobulin | 15q21-q22.2 | Q-PCR | 5'-GTGCTCGCGCTACTCTCTCT-3' | 5'-TCAATGTCGGATGGATGAAA-3' | 153 |
β-3A-adaptin (K1*) | 5q14.1 | DNA cleavage control | 5'-TGCCCTCTGGACTGGAACCT-3' | 5'-CCTGAGCCCAGCCCAAGTC-3' | 445 |
RARβ2 (K2**) | 3p24.2 | DNA integrity control | 5'-AGAGTTTGATGGAGTTGGGT-3' | 5'-CATTCGGTTTGGGTCAATCC-3' | 229 |
PCR based Methylation sensitive restriction analysis (MSRA)
Mutation analysis
Quantitative Real-time PCR (Q-PCR)
Immunohistochemistry
Statistical Analysis of Clinical Data
Results
Deletion analysis of candidate TSGs loci
Group-A | Group-B | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PHF2
|
FANCC
|
PTCH1
|
XPA
|
PHF2
|
FANCC
|
PTCH1
|
XPA
| ||||||||||
D+
|
D-
|
D+
|
D-
|
D+
|
D-
|
D+
|
D-
|
D+
|
D-
|
D+
|
D-
|
D+
|
D-
|
D+
|
D-
| ||
PHF2
|
D+
| - | - | 9 | 11 | 6 | 14 | 6 | 14 | - | - | 13 | 12 | 5 | 20 | 6 | 19 |
D-
| 13 | 14 | 8 | 19 | 4 | 23 | 16 | 18 | 11 | 23 | 6 | 28 | |||||
p value
| - | 0.83 | 0.98 | 0.21 | - | 0.71 | 0.29 | 0.55 | |||||||||
FANCC
|
D+
| - | - | - | - | 5 | 17 | 5 | 17 | - | - | - | - | 7 | 22 | 5 | 24 |
D-
| 9 | 16 | 5 | 20 | 9 | 21 | 7 | 23 | |||||||||
p value
| - | - | 0.32 | 0.82 | - | - | 0.61 | 0.56 | |||||||||
PTCH1
|
D+
| - | - | - | - | - | - | 6 | 8 | - | - | - | - | - | - | 9 | 7 |
D-
| 4 | 29 | 3 | 40 | |||||||||||||
p value
| - | - | - |
0.02*
| - | - | - |
0.00003*
|
Promoter Methylation analysis
Group-A | Group-B | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PHF2
|
FANCC
|
PTCH1
|
XPA
|
PHF2
|
FANCC
|
PTCH1
|
XPA
| ||||||||||
M+
|
M-
|
M+
|
M-
|
M+
|
M-
|
M+
|
M-
|
M+
|
M-
|
M+
|
M-
|
M+
|
M-
|
M+
|
M-
| ||
PHF2
|
M+
| - | - | 6 | 4 | 2 | 8 | 4 | 6 | - | - | 10 | 3 | 7 | 6 | 5 | 8 |
M-
| 8 | 29 | 13 | 24 | 4 | 33 | 13 | 33 | 14 | 32 | 9 | 37 | |||||
p value
| - |
0.02*
| 0.36 |
0.03*
| - |
0.001*
| 0.12 | 0.16 | |||||||||
FANCC
|
M+
| - | - | - | - | 6 | 8 | 7 | 7 | - | - | - | - | 7 | 16 | 7 | 16 |
M-
| 9 | 24 | 1 | 32 | 14 | 22 | 7 | 29 | |||||||||
p value
| - | - | 0.29 |
0.0001*
| - | - | 0.51 | 0.33 | |||||||||
PTCH1
|
M+
| - | - | - | - | - | - | 4 | 11 | - | - | - | - | - | - | 9 | 12 |
M-
| 4 | 28 | 5 | 33 | |||||||||||||
p value
| - | - | - | 0.23 | - | - | - |
0.01*
|
Mutation analysis of PTCH1 Exon-23
Association between overall alterations of candidate TSGs
Expression analysis of the candidate genes
FANCC alteration | PTCH1 alteration | |||
---|---|---|---|---|
Sample No.
|
Deletion/Methylation
|
FANCC protein expression
|
Deletion/Methylation
|
PTCH1 protein expression
|
1186 | +/- | - | -/- | +++ |
374 | -/+ | - | -/+ | - |
4187 | +/- | + | -/+ | - |
3266 | +/+ | - | -/- | +++ |
5451 | -/- | +++ | -/- | +++ |
5596 | -/- | +++ | -/+ | - |
3156 | +/+ | - | -/- | +++ |
4604 | +/+ | - | +/+ | - |
4131 | -/+ | ++ | +/- | - |
2490 | +/- | - | -/+ | - |
2400 | +/+ | - | -/+ | ++ |
796 | +/- | ++ | -/+ | - |
880 | -/- | +++ | +/+ | - |
314 | +/- | ++ | +/- | ++ |
5337 | +/- | - | -/- | +++ |
1865 | +/+ | - | -/+ | - |
4671 | -/- | +++ | +/- | + |
3025 | +/+ | - | -/+ | - |
6155 | -/+ | - | -/- | +++ |
1144 | -/- | +++ | -/+ | - |
P value
|
P = 0.004 *
|
P = 0.001 *
|